Manuscripts
Showing 1530 manuscripts.
Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men
Citation
Catherine N Le, Paul Britto, Sean S Brummel, Risa M Hoffman, Jonathan Z Li, Patricia M Flynn, Taha E Taha, Anne Coletti, Mary Glenn Fowler, Ronald J Bosch, Rajesh T Gandhi, Karin L Klingman, James A McIntyre, Judith S Currier. Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men. AIDS. 2019. 33: 2149-2156. PMID: 31373919Year
2019
Journal
AIDS
Study
1077HS
Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study
Citation
Eliza D Hompe, Denise L Jacobson, Joshua A Eudailey, Kevin Butler, Whitney Edwards, Justin Pollara, Sean S Brummel, Genevieve G Fouda, Lemeck Chinula, Melvin Kamanga, Aarti Kinikar, Dhayendre Moodley, Maxensia Owor, Mary Glenn Fowler, Sallie R Permar. Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study. mSphere. 2019. 4: e00716-19. PMID: 31645430Year
2019
Journal
mSphere
Study
1077BF, 1077FF
Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate With Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy.
Citation
M McManus, J Henderson, A Gautam, R Brody, ER Weiss, D Persaud, E Mick, K Lazuriaga, PACTG 356 Investigators. Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate With Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy.. Clinical Infectious Diseases. 2019. PMID: 30668843Year
2019
Journal
Clinical Infectious Diseases
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Citation
J Lommerse, D Clarke, T Kerbusch, H Merdjan, H Witjes, H Teppler, M Mirochnick, EP Acosta, L Wenning, S Nachman, A Chain. Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing. CPT: pharmacometrics & systems pharmacology. 2019. 8: 643-653. PMID: 31215170Year
2019
Journal
CPT: pharmacometrics & systems pharmacology
Study
P1066
Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe
Citation
L Stranix-Chibanda, S Brummel, J Pilotto, M Mutambanengwe, V Chanaiwa, T Mhembere, M Kamateeka, J Aizire, G Masheto, R Chamanga, M Maluwa, S Hanley, E Joao, G Theron, N Nevrekar, M Nyati, B Santos, L Aurpibul, M Mubiana-Mbewe, R Oliveira, T Anekthananon, P Mlay, K Angelidou, C Tierney, L Ziemba, A Coletti, K McCarthy, M Basar, N Chakhtoura, R Browning, J Currier, MG Fowler, P Flynn, PROMISE study team. Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe. AIDS and Behavior. 2019. 23: 2522-2531. PMID: 31399793Year
2019
Journal
AIDS and Behavior
Study
1077BF, 1077FF, 1077HS
Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial
Citation
Dorothy Sebikari, Mona Farhad, Terry Fenton, Maxensia Owor, Jeffrey S A Stringer, Min Qin, Nahida Chakhtoura, Benjamin H Chi, Friday Saidi, Neetal Nevrekar, Avy Violari, Tsungai Chipato, James McIntyre, Dhayendre Moodley, Taha E Taha, Gerhard Theron, Mary Glenn Fowler. Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial. Journal of Acquired Immune Deficiency Syndromes. 2019. 81: 521-532. PMID: 31295174Year
2019
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
1077BF, 1077FF
Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women
Citation
Pamela M Murnane, Peter Bacchetti, Judith S Currier, Sean Brummel, Hideaki Okochi, Nhi Phung, Alexander Louie, Karen Kuncze, Risa M Hoffman, Teacler Nematadzira, Dean K Soko, Maxensia Owor, Friday Saidi, Patricia M Flynn, Mary G Fowler, Monica Gandhi. Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. AIDS. 2019. 33: 1657-1662. PMID: 31021852Year
2019
Journal
AIDS
Study
1077BF
Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study
Citation
Michael J Boivin, Limbika Maliwichi-Senganimalunje, Lillian W Ogwang, Rachel Kawalazira, Alla Sikorskii, Itziar Familiar-Lopez, Agatha Kuteesa, Mary Nyakato, Alex Mutebe, Jackie L Namukooli, MacPherson Mallewa, Horacio Ruiseñor-Escudero, Jim Aizire, MG Fowler, Taha E Taha, Mary G Fowler. Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study. Lancet HIV. 2019. 6: e518-530. PMID: 31122797Year
2019
Journal
Lancet HIV
Study
1077BF
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger than 3 Years.
Citation
M Bwakura Dangarembizi, P Samson, EV Capparelli, CB Moore, P Jean-Philippe, SA Spector, N Chakhtoura, A Benns, B Zimmer, L Purdue, C Jackson, C Wallis, JL Libous, EG Chadwick, IMPAACT P1070 Study Team. Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger than 3 Years.. Journal of Acquired Immune Deficiency Syndromes. 2019. 81: 473-480. PMID: 31241542Year
2019
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1070